et al. Projecting cancer incidence and deaths to 2030: the
unexpected burden of thyroid, liver, and pancreas cancers in the United
States. Cancer Res.
74, 2913–2921 (2014)
et al. Core signaling pathways in human pancreatic cancers revealed
by global genomic analyses. Science
321, 1801–1806 (2008)
Campbell, P. J.
et al. The patterns and dynamics of genomic instability in
metastatic pancreatic cancer. Nature
467, 1109–1113 (2010)
Biankin, A. V.
et al. Pancreatic cancer genomes reveal aberrations in axon guidance
pathway genes. Nature
491, 399–405 (2012)
et al. Whole genomes redefine the mutational landscape of pancreatic
518, 495–501 (2015)
Witkiewicz, A. K.
et al. Whole-exome sequencing of pancreatic cancer defines genetic
diversity and therapeutic targets. Nat. Commun.
6, 6744 (2015)
et al. Genomic analyses identify molecular subtypes of pancreatic
531, 47–52 (2016)
Makohon-Moore, A. P.
et al. Limited heterogeneity of known driver gene mutations among
the metastases of individual patients with pancreatic cancer.
49, 358–366 (2017)
Jackson, E. L.
et al. Analysis of lung tumor initiation and progression using
conditional expression of oncogenic K-ras. Genes Dev.
15, 3243–3248 (2001)
et al. A next-generation dual-recombinase system for time- and
host-specific targeting of pancreatic cancer. Nat. Med.
20, 1340–1347 (2014)
Pérez-Mancera, P. A.
et al. The deubiquitinase USP9X suppresses pancreatic ductal
486, 266–270 (2012)
Mann, K. M.
et al. Sleeping Beauty mutagenesis reveals cooperating mutations and
pathways in pancreatic adenocarcinoma. Proc. Natl Acad. Sci.
109, 5934–5941 (2012)
et al. A conditional piggyBac transposition system for
genetic screening in mice identifies oncogenic networks in pancreatic
cancer. Nat. Genet.
47, 47–56 (2015)
Korbel, J. O. &
Campbell, P. J.
Criteria for inference of chromothripsis in cancer genomes.
152, 1226–1236 (2013)
et al. A renewed model of pancreatic cancer evolution based on
genomic rearrangement patterns. Nature
538, 378–382 (2016)
et al. Amplifications of both c-Ki-ras with a point mutation and
c-myc in a primary pancreatic cancer and its metastatic tumors in lymph
nodes. Jpn. J. Cancer Res.
77, 370–375 (1986)
et al. Detailed genomic mapping and expression analyses of 12p
amplifications in pancreatic carcinomas reveal a 3.5-Mb target region for
amplification. Genes Chromosom. Cancer
34, 211–223 (2002)
Sarkisian, C. J.
et al. Dose-dependent oncogene-induced senescence in vivo and
its evasion during mammary tumorigenesis. Nat. Cell Biol.
9, 493–505 (2007)
Junttila, M. R.
et al. Selective activation of p53-mediated tumour suppression in
high-grade tumours. Nature
468, 567–571 (2010)
Feldser, D. M. et al.
Stage-specific sensitivity to p53 restoration during lung cancer
468, 572–575 (2010)
et al. A genetic progression model of Braf(V600E)-induced intestinal
tumorigenesis reveals targets for therapeutic intervention.
24, 15–29 (2013)
Rhim, A. D.
et al. EMT and dissemination precede pancreatic tumor
148, 349–361 (2012)
Stathis, A. &
Moore, M. J.
Advanced pancreatic carcinoma: current treatment and future
challenges. Nat. Rev. Clin. Oncol.
7, 163–172 (2010)
et al. Distant metastasis occurs late during the genetic evolution
of pancreatic cancer. Nature
467, 1114–1117 (2010)
et al. IKKα controls p52/RelB at the skp2 gene promoter
to regulate G1- to S-phase progression. EMBO J.
25, 3801–3812 (2006)
et al. Nuclear protein 1 promotes pancreatic cancer development and
protects cells from stress by inhibiting apoptosis. J. Clin.
122, 2092–2103 (2012)
Redston, M. S. et al. p53
mutations in pancreatic carcinoma and evidence of common involvement of
homocopolymer tracts in DNA microdeletions. Cancer Res.
54, 3025–3033 (1994)
Collisson, E. A.
et al. Subtypes of pancreatic ductal adenocarcinoma and their
differing responses to therapy. Nat. Med.
17, 500–503 (2011)
Moffitt, R. A.
et al. Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma.
47, 1168–1178 (2015)
et al. Multiplexed pancreatic genome engineering and cancer
induction by transfection-based CRISPR/Cas9 delivery in mice.
7, 10770 (2016)
Morohoshi, T., Held, G. & Klöppel, G.
Exocrine pancreatic tumours and their histological classification. A study
based on 167 autopsy and 97 surgical cases. Histopathology
7, 645–661 (1983)
Iacobuzio-Donahue, C. A.
et al. DPC4 gene status of the primary carcinoma correlates with
patterns of failure in patients with pancreatic cancer. J. Clin.
27, 1806–1813 (2009)
Winter, J. M.
et al. Absence of E-cadherin expression distinguishes noncohesive
from cohesive pancreatic cancer. Clin. Cancer Res.
14, 412–418 (2008)
Hruban, R. H.
et al. Pathology of genetically engineered mouse models of
pancreatic exocrine cancer: consensus report and recommendations.
66, 95–106 (2006)
Hingorani, S. R.
et al. Preinvasive and invasive ductal pancreatic cancer and its
early detection in the mouse. Cancer Cell
4, 437–450 (2003)
et al. Ptf1a is essential for the differentiation of GABAergic and
glycinergic amacrine cells and horizontal cells in the mouse retina.
134, 1151–1160 (2007)
Aguirre, A. J.
et al. Activated Kras and Ink4a/Arf deficiency
cooperate to produce metastatic pancreatic ductal adenocarcinoma.
17, 3112–3126 (2003)
et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a
conditional mouse model for breast cancer. Nat. Genet.
29, 418–425 (2001)
Lee, C. L. et al.
Generation of primary tumors with Flp recombinase in FRT-flanked p53
mice. Dis. Model. Mech.
5, 397–402 (2012)
Chytil, A., Magnuson, M. A., Wright, C. V. & Moses, H. L.
Conditional inactivation of the TGF-β type II receptor using
32, 73–75 (2002)
Bronner, I. F.,
Quail, M. A., Turner, D. J. & Swerdlow, H.
Improved protocols for Illumina sequencing. Curr. Protoc. Hum.
80, 18.2.1–18.2.42 (2014)
Stephens, P. J.
et al. Massive genomic rearrangement acquired in a single
catastrophic event during cancer development. Cell
144, 27–40 (2011)
Jentsch, I., Adler, I. D., Carter, N. P. & Speicher, M. R.
Karyotyping mouse chromosomes by multiplex-FISH (M-FISH).
9, 211–214 (2001)
Keane, T. M.
et al. Mouse genomic variation and its effect on phenotypes and gene
477, 289–294 (2011)
Ye, K., Schulz, M. H., Long, Q.,
Apweiler, R. &
Pindel: a pattern growth approach to detect break points of large deletions
and medium sized insertions from paired-end short reads.
25, 2865–2871 (2009)
et al. The Cancer Cell Line Encyclopedia enables predictive
modelling of anticancer drug sensitivity. Nature
483, 603–607 (2012)
Alexandrov, L. B.
et al. Signatures of mutational processes in human cancer.
500, 415–421 (2013)
Vieth, B., Enard, W. & Hellmann, I.
The impact of amplification on differential expression analyses by
RNA-seq. Sci. Rep.
6, 25533 (2016)
Macosko, E. Z.
et al. Highly parallel genome-wide expression profiling of
individual cells using nanoliter droplets. Cell
161, 1202–1214 (2015)
Love, M. I., Huber, W. & Anders, S.
Moderated estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol.
15, 550 (2014)
Huang, W., Sherman, B. T. & Lempicki, R. A.
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat. Protocols
4, 44–57 (2009)
et al. Gene set enrichment analysis: a knowledge-based approach for
interpreting genome-wide expression profiles. Proc. Natl Acad.
102, 15545–15550 (2005)
Schaefer, C. F.
et al. PID: the Pathway Interaction Database. Nucleic
37, D674–D679 (2009)
Du, P., Kibbe, W. A. & Lin, S.
M. lumi: a pipeline for processing Illumina microarray.
24, 1547–1548 (2008)
Ritchie, M. E.
et al. limma powers differential expression analyses for
RNA-sequencing and microarray studies. Nucleic Acids Res.
43, e47 (2015)
Friedrich, M. J.
et al. Genome-wide transposon screening and quantitative insertion
site sequencing for cancer gene discovery in mice. Nat.
12, 289–309 (2017)
Meerbrey, K. L.
et al. The pINDUCER lentiviral toolkit for inducible RNA
interference in vitro and in vivo. Proc. Natl Acad. Sci.
108, 3665–3670 (2011)
Kutner, R. H., Zhang, X. Y. & Reiser, J.
Production, concentration and titration of pseudotyped HIV-1-based
lentiviral vectors. Nat. Protocols
4, 495–505 (2009)
et al. CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput
functional cancer genomics in mice. Proc. Natl Acad. Sci.
112, 13982–13987 (2015)
et al. The cBio cancer genomics portal: an open platform for
exploring multidimensional cancer genomics data. Cancer
2, 401–404 (2012)
et al. Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci. Signal.
6, pl1 (2013)
et al. Tissue-based map of the human proteome.
347, 1260419 (2015)
Hoadley, K. A.
et al. Multiplatform analysis of 12 cancer types reveals molecular
classification within and across tissues of origin. Cell
158, 929–944 (2014)